general

general

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - Eli Lilly

Ventyx Biosciences Acquired by Eli Lilly, Expands Capabilities in Inflammatory Therapies In a significant development in the pharmaceutical industry, Ventyx Biosciences, a biopharmaceutical company focused on developing novel therapies for chronic inflammation, has been acquired by Eli Lilly and Company. This acquisition marks an exciting milestone for both companies, as

By Lau Chi Fung